Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Return on Assets (2021 - 2025)

Historic Return on Assets for TScan Therapeutics (TCRX) over the last 5 years, with Q3 2025 value amounting to 0.5%.

  • TScan Therapeutics' Return on Assets fell 2000.0% to 0.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.5%, marking a year-over-year decrease of 2000.0%. This contributed to the annual value of 0.39% for FY2024, which is 100.0% down from last year.
  • Latest data reveals that TScan Therapeutics reported Return on Assets of 0.5% as of Q3 2025, which was down 2000.0% from 0.43% recorded in Q2 2025.
  • TScan Therapeutics' Return on Assets' 5-year high stood at 0.25% during Q4 2021, with a 5-year trough of 0.5% in Q3 2025.
  • Moreover, its 5-year median value for Return on Assets was 0.35% (2024), whereas its average is 0.35%.
  • As far as peak fluctuations go, TScan Therapeutics' Return on Assets skyrocketed by 1000bps in 2023, and later plummeted by -2000bps in 2025.
  • TScan Therapeutics' Return on Assets (Quarter) stood at 0.25% in 2021, then tumbled by -47bps to 0.36% in 2022, then increased by 13bps to 0.32% in 2023, then decreased by -11bps to 0.35% in 2024, then plummeted by -44bps to 0.5% in 2025.
  • Its Return on Assets was 0.5% in Q3 2025, compared to 0.43% in Q2 2025 and 0.37% in Q1 2025.